The trajectory of conditional, recurrence-free, and long-term survival in a complete 10-year cohort of patients with advanced ovarian cancer.

IF 2.7 3区 医学 Q3 ONCOLOGY
Nina Groes Kofoed, Henrik Falconer, Matteo Bottai, Sahar Salehi
{"title":"The trajectory of conditional, recurrence-free, and long-term survival in a complete 10-year cohort of patients with advanced ovarian cancer.","authors":"Nina Groes Kofoed, Henrik Falconer, Matteo Bottai, Sahar Salehi","doi":"10.2340/1651-226X.2025.42994","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The prognosis in advanced ovarian cancer is generally poor since the majority experience recurrence. Nevertheless, there is a chance of cure and very long-term survival may be achieved. However, traditional survival metrics do not account for the dynamic changes in prognosis over time. Our objectives were to examine conditional, very long-term and recurrence-free survival, in addition risk-factors for recurrence.</p><p><strong>Methods: </strong>In this observational study, all patients diagnosed with advanced ovarian cancer between 2009 and 2018 in the Stockholm/Gotland region, Sweden, were identified in the Swedish Quality Registry of Gynecologic Cancer. Conditional and recurrence-free survival were estimated with the Kaplan Meier method. The association between predefined clinical factors and hazard of death was analysed with Cox regression yielding hazard ratio (HR) with 95% confidence interval (CI).</p><p><strong>Results: </strong>A total of 888 patients were analysed of which 87.0% (n = 740) experienced a recurrence and 8.5 % (n = 76) were alive > 10 years. The 5-year conditional survival increased from 33.0% (95% CI: 30-36) in patients who had survived 1 year to 57.0% (95% CI: 50-63) in patients who had already survived 5 years. The median recurrence-free survival was 18 months (95% CI: 16-19). Risk factors associated with recurrence included any residual tumour (> 10 mm; HR: 2.15; 95% CI: 1.65 to 2.80) and evidence of disease at end of first line treatment (HR: 2.40; 95% CI: 1.97 to 2.93; p < 0.001).</p><p><strong>Interpretation: </strong>Conditional survival improves significantly with time survived following an advanced ovarian cancer diagnosis. Most patients experience relapse within 1 year after completing first-line treatment, nevertheless long-term survival is possible.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"64 ","pages":"423-430"},"PeriodicalIF":2.7000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11931853/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Oncologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2340/1651-226X.2025.42994","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The prognosis in advanced ovarian cancer is generally poor since the majority experience recurrence. Nevertheless, there is a chance of cure and very long-term survival may be achieved. However, traditional survival metrics do not account for the dynamic changes in prognosis over time. Our objectives were to examine conditional, very long-term and recurrence-free survival, in addition risk-factors for recurrence.

Methods: In this observational study, all patients diagnosed with advanced ovarian cancer between 2009 and 2018 in the Stockholm/Gotland region, Sweden, were identified in the Swedish Quality Registry of Gynecologic Cancer. Conditional and recurrence-free survival were estimated with the Kaplan Meier method. The association between predefined clinical factors and hazard of death was analysed with Cox regression yielding hazard ratio (HR) with 95% confidence interval (CI).

Results: A total of 888 patients were analysed of which 87.0% (n = 740) experienced a recurrence and 8.5 % (n = 76) were alive > 10 years. The 5-year conditional survival increased from 33.0% (95% CI: 30-36) in patients who had survived 1 year to 57.0% (95% CI: 50-63) in patients who had already survived 5 years. The median recurrence-free survival was 18 months (95% CI: 16-19). Risk factors associated with recurrence included any residual tumour (> 10 mm; HR: 2.15; 95% CI: 1.65 to 2.80) and evidence of disease at end of first line treatment (HR: 2.40; 95% CI: 1.97 to 2.93; p < 0.001).

Interpretation: Conditional survival improves significantly with time survived following an advanced ovarian cancer diagnosis. Most patients experience relapse within 1 year after completing first-line treatment, nevertheless long-term survival is possible.

在一个完整的10年晚期卵巢癌患者队列中,条件、无复发和长期生存的轨迹。
背景:晚期卵巢癌的预后一般较差,多数复发。尽管如此,还是有治愈的机会,并且有可能实现长期生存。然而,传统的生存指标不能解释预后随时间的动态变化。我们的目标是检查有条件的、非常长期的和无复发的生存,以及复发的危险因素。方法:在这项观察性研究中,2009年至2018年期间在瑞典斯德哥尔摩/哥特兰地区诊断为晚期卵巢癌的所有患者均在瑞典妇科癌症质量登记处进行了鉴定。用Kaplan Meier法估计条件生存期和无复发生存期。采用Cox回归分析预先确定的临床因素与死亡危险之间的关联,得出95%可信区间的风险比(HR)。结果:共分析888例患者,其中87.0% (n = 740)复发,8.5% (n = 76)存活10年以上。存活1年患者的5年条件生存率从33.0% (95% CI: 30-36)增加到已存活5年患者的57.0% (95% CI: 50-63)。中位无复发生存期为18个月(95% CI: 16-19)。与复发相关的危险因素包括任何残留肿瘤(bbb10 mm;人力资源:2.15;95% CI: 1.65 - 2.80)和一线治疗结束时疾病的证据(HR: 2.40;95% CI: 1.97 ~ 2.93;P < 0.001)。结论:晚期卵巢癌诊断后的条件生存率随着生存时间的延长而显著提高。大多数患者在完成一线治疗后1年内复发,但长期生存是可能的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Oncologica
Acta Oncologica 医学-肿瘤学
CiteScore
4.30
自引率
3.20%
发文量
301
审稿时长
3 months
期刊介绍: Acta Oncologica is a journal for the clinical oncologist and accepts articles within all fields of clinical cancer research. Articles on tumour pathology, experimental oncology, radiobiology, cancer epidemiology and medical radio physics are also welcome, especially if they have a clinical aim or interest. Scientific articles on cancer nursing and psychological or social aspects of cancer are also welcomed. Extensive material may be published as Supplements, for which special conditions apply.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信